Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anhydrous dextrose + aspirin + nitroglycerin + albuterol sulfate + epinephrine + diphenhydramine is a **small-molecule combination emergency kit product** used in dental and office settings for acute medical emergencies. The combination includes **epinephrine** for emergency treatment of type I allergic reactions and anaphylaxis, **albuterol sulfate** as a beta-2 adrenergic bronchodilator for bronchospasm, **diphenhydramine** as an H1 antihistamine for allergic symptoms, **nitroglycerin** as a vasodilator for angina or chest pain, **aspirin** as an analgesic and antiplatelet agent, and **anhydrous dextrose** as a rapidly available carbohydrate component. Based on the provided context, the most relevant intended emergency indication for the exact combination is support of management of **allergic reactions including anaphylaxis**, with epinephrine serving as the principal lifesaving pharmacologic component. The product is marketed as a preassembled emergency kit rather than a novel molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anhydrous dextrose + aspirin + nitroglycerin + albuterol sulfate + epinephrine + diphenhydramine.